RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Novo Nordisk A/S Equity 2024

Novo Nordisk A/S Equity

106.56 B DKK

Novo Nordisk A/S Dividend yield

1.63 %

Ticker

NOVO B.CO

ISIN

DK0060534915

WKN

A1XA8R

In 2024, Novo Nordisk A/S's equity was 106.56 B DKK, a 27.64% increase from the 83.49 B DKK equity in the previous year.

Novo Nordisk A/S Aktienanalyse

What does Novo Nordisk A/S do?

Novo Nordisk A/S is a Danish company specializing in the production of insulin and other diabetes medications. It was founded in 1923 and has its headquarters in Bagsværd, Denmark. Novo Nordisk is the world's largest manufacturer of insulin and one of the key players in the field of diabetes treatment. Novo Nordisk A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Novo Nordisk A/S's Equity

Novo Nordisk A/S's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Novo Nordisk A/S's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Novo Nordisk A/S's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Novo Nordisk A/S's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Novo Nordisk A/S’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Novo Nordisk A/S Stock

What is the equity of Novo Nordisk A/S this year?

Novo Nordisk A/S has equity of 106.56 B DKK this year.

What was the equity of Novo Nordisk A/S compared to the previous year?

The equity of Novo Nordisk A/S has increased/decreased by 27.64% increased compared to the previous year.

What impact does a high equity have on investors of Novo Nordisk A/S?

A high equity is advantageous for investors of Novo Nordisk A/S as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Novo Nordisk A/S?

A low equity can be a risk for investors of Novo Nordisk A/S, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Novo Nordisk A/S affect the company?

An increase in equity of Novo Nordisk A/S can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Novo Nordisk A/S affect the company?

A reduction in equity of Novo Nordisk A/S can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Novo Nordisk A/S?

Some factors that can affect the equity of Novo Nordisk A/S include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Novo Nordisk A/S so important for investors?

The equity of Novo Nordisk A/S is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Novo Nordisk A/S take to change the equity?

To change equity, Novo Nordisk A/S can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Novo Nordisk A/S pay?

Over the past 12 months, Novo Nordisk A/S paid a dividend of 14.15 DKK . This corresponds to a dividend yield of about 1.63 %. For the coming 12 months, Novo Nordisk A/S is expected to pay a dividend of 14.94 DKK.

What is the dividend yield of Novo Nordisk A/S?

The current dividend yield of Novo Nordisk A/S is 1.63 %.

When does Novo Nordisk A/S pay dividends?

Novo Nordisk A/S pays a quarterly dividend. This is distributed in the months of September, April, September, April.

How secure is the dividend of Novo Nordisk A/S?

Novo Nordisk A/S paid dividends every year for the past 26 years.

What is the dividend of Novo Nordisk A/S?

For the upcoming 12 months, dividends amounting to 14.94 DKK are expected. This corresponds to a dividend yield of 1.72 %.

In which sector is Novo Nordisk A/S located?

Novo Nordisk A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Novo Nordisk A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Novo Nordisk A/S from 3/26/2024 amounting to 6.4 DKK, you needed to have the stock in your portfolio before the ex-date on 3/22/2024.

When did Novo Nordisk A/S pay the last dividend?

The last dividend was paid out on 3/26/2024.

What was the dividend of Novo Nordisk A/S in the year 2023?

In the year 2023, Novo Nordisk A/S distributed 11.15 DKK as dividends.

In which currency does Novo Nordisk A/S pay out the dividend?

The dividends of Novo Nordisk A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Novo Nordisk A/S stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Novo Nordisk A/S

Our stock analysis for Novo Nordisk A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novo Nordisk A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.